There are currently 20 ongoing clinical trials involving Narcolepsy
Of the 20 trials,8 trials are in Phase II
Furthermore, 5 trials are in Phase IV
The global pharmaceutical industry is steadily developing new drugs for Narcolepsy, a Central Nervous System indication. The largest number of ongoing clinical trials for Narcolepsy is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Narcolepsy-related drug trials.
Jazz Pharmaceuticals Plc: The leading ongoing Narcolepsy related clinical trial sponsor
Jazz Pharmaceuticals Plc is the top sponsor for Narcolepsy-related ongoing clinical trials.
NLS Pharmaceutics AG, Axsome Therapeutics Inc, Emory University, and Takeda Pharmaceutical Co Ltd are among other notable clinical trial sponsors involved in Narcolepsy. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Narcolepsy
Sodium oxybate (Xyrem), Pitolisant hydrochloride (Wakix, Ozawade), and Solriamfetol hydrochloride (Sunosi) are among the key marketed drugs involving Narcolepsy.
Sodium oxybate (Xyrem) is a sodium salt of gamma hydroxybutyrate, acts as central nervous system depressant. It functions via Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid (GABA) B Receptor or GABBR) Agonist mechanism of action. It is formulated as solution for oral route of administration. Xyrem is indicated for the treatment of cataplexy in narcolepsy and for the treatment of excessive daytime sleepiness (EDS) in narcolepsy. Xyrem was first approved in 2002 and is marketed globally including the US, the UK, France, and Germany by Jazz Pharmaceuticals Inc, and UCB Pharma Ltd.
Pitolisant hydrochloride (Wakix, Ozawade) is a central nervous system drug. It functions via Histamine H3 Receptor (G Protein Coupled Receptor 97 or GPCR97 or HRH3) Antagonist mechanism of action. Pitolisant hydrochloride is formulated as film-coated tablets for oral route of administration. Wakix is indicated in adults for the treatment of narcolepsy with or without cataplexy. Ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by, or who have not tolerated, OSA primary therapy, such as continuous positive airway pressure (CPAP). Pitolisant hydrochloride was first approved in 2016 and is marketed globally including the US, the UK, France, and Germany by Harmony Biosciences Holdings Inc.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer